GSK/Innoviva COPD combo passes Phase III test

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Innoviva Inc. (NASDAQ:INVA) said fluticasone furoate/umeclidinium/vilanterol met the co-primary endpoints in the Phase III FULFIL

Read the full 207 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE